AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$EW

Lippis Daniel J. sold $54K of EW

Lippis Daniel J. (CVP, TAVR) sold 619 shares of Edwards Lifesciences Corp (EW) at $87.51 on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lippis Daniel J.
Published Sep 11, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EW
Neutral
high confidence
Mentioned
$EW
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

The sale is modest and unlikely to affect EW's valuation, but it adds to the ongoing monitoring of insider behavior.

02

Market read

Insider sale of $54K is a routine disclosure with limited trading relevance.

03

What to watch

Potential upcoming earnings or product announcements that may amplify the impact of any insider activity.

Relevance 2/10Novelty 5/10Timing: reported on 2026-09-11 (same day filing)

Background

Form 4 filings disclose insider transactions; a sale by a senior officer is routinely reported.

Company-level read

Ticker impact

$EWNeutralHigh confidence
Context

Officer Daniel Lippis sold 619 shares of Edwards Lifesciences at $87.51, reducing his stake to 40,034 shares.

Expected impact

little to no immediate effect on EW price

Evidence & confidence

The transaction size (~$54k) is small relative to market cap; typical insider sales of this magnitude rarely move the stock.

Market effects

Sector

None; Edwards Lifesciences operates in medical devices, and the sale does not signal sector trends.

Regional

None; the filing is U.S.-focused and does not affect regional markets.

Global

Minimal; only relevant to investors tracking EW insider activity.

Counterpoint

What could challenge this read

If the insider expects upcoming negative news, the sale could foreshadow a short‑term dip.

Key entities

  • Company
    Edwards Lifesciences Corp

    Medical device manufacturer (ticker EW).

  • Insider
    Daniel J. Lippis

    Chief Vice President, Transcatheter Aortic Valve Replacement (TAVR) at EW.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EW insider trading history →

Related articles

OCT 5
$EWMed

FDA Approves First Heart Valve to Keep Pace With Children's Growth

The FDA approved Edwards Lifesciences' Autus Size-Adjustable Valve, the first heart valve designed to expand with a child's growth, for pediatric patients with congenital pulmonary valve disease. The valve can be implanted at 13 mm and expanded to 22 mm, potentially reducing repeat open-heart surgeries. The approval was based on a pivotal trial with 62 patients, showing acceptable hemodynamic performance and no major complications at 6 months.

ajmc.com2 min
OCT 2
$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min